- Home
- BOE vs KROS Comparison
BOE vs KROS Comparison
Compare BOE & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOE
- KROS
- Stock Information
- Founded
- BOE 2005
- KROS 2015
- Country
- BOE United States
- KROS United States
- Employees
- BOE N/A
- KROS N/A
- Industry
- BOE Trusts Except Educational Religious and Charitable
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- BOE Finance
- KROS Health Care
- Exchange
- BOE Nasdaq
- KROS Nasdaq
- Market Cap
- BOE 634.0M
- KROS 558.9M
- IPO Year
- BOE N/A
- KROS 2020
- Fundamental
- Price
- BOE $11.51
- KROS $13.45
- Analyst Decision
- BOE
- KROS Buy
- Analyst Count
- BOE 0
- KROS 13
- Target Price
- BOE N/A
- KROS $20.63
- AVG Volume (30 Days)
- BOE 166.1K
- KROS 603.2K
- Earning Date
- BOE 01-01-0001
- KROS 08-06-2025
- Dividend Yield
- BOE 7.30%
- KROS N/A
- EPS Growth
- BOE N/A
- KROS N/A
- EPS
- BOE N/A
- KROS 0.11
- Revenue
- BOE N/A
- KROS $214,713,000.00
- Revenue This Year
- BOE N/A
- KROS $5,006.76
- Revenue Next Year
- BOE N/A
- KROS N/A
- P/E Ratio
- BOE N/A
- KROS $123.44
- Revenue Growth
- BOE N/A
- KROS 91657.70
- 52 Week Low
- BOE $8.80
- KROS $9.12
- 52 Week High
- BOE $10.48
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- BOE 69.16
- KROS 43.42
- Support Level
- BOE $11.12
- KROS $13.24
- Resistance Level
- BOE $11.54
- KROS $13.77
- Average True Range (ATR)
- BOE 0.10
- KROS 0.38
- MACD
- BOE 0.03
- KROS -0.04
- Stochastic Oscillator
- BOE 94.44
- KROS 28.00
About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest
Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.